The controversial and never-proven-effective drug to treat Alzheimer's disease, aducanumab (Aduhelm) has been discontinued.
FDA upgrades Leqembi for AD from accelerated to traditional approval based on latest clinical data.
Using AI systems for pattern recognition in early diagnosis of dementia shows the potential of this tool.
A Congressional report on the approval of the Alzheimer's drug Aduhelm identified serious concerns about the FDA's processes
A new treatment for Alzheimer's Disease is promising, but we're not there yet.
Can you reduce the risk of cognitive decline with dietary supplements?
A stunning case of possible fraud in Alzheimer's research reinforces the need for scientific rigor at every level.
COVID infection has been associated with an increased risk of neurodegenerative and neurovascular disease - another reason to keep our eye on this serious illness.
An important decision has been made about a controversial new drug to treat Alzheimer's disease.
Press releases often outpace the data. Here are some examples of over-enthusiastic reporting on extremely preliminary research.